摘要
目的分析瑞舒伐他汀钙片联合曲美他嗪治疗冠心病的临床疗效。方法选取2019年8月—2021年8月期间在该院治疗的94例冠心病患者临床资料进行回顾性分析,根据随机数字表法,按照1∶1比例分成对照组和研究组,对照组采用曲美他嗪治疗,研究组采用瑞舒伐他汀钙片联合曲美他嗪治疗,对比两组治疗效果和治疗前后的心功能指标,观察两组不良反应情况。结果研究组和对照组治疗有效率分别为95.74%、80.85%,研究组高于对照组,差异有统计学意义(χ^(2)=5.045,P<0.05)。治疗前,两组患者心功能指标水平比较,差异无统计学意义(P>0.05);治疗后,两组均有所改善,且研究组的LVEF高于对照组,LVEDD、LVESD低于对照组,差异有统计学意义(P<0.05)。研究组和对照组不良反应发生率分别为6.38%、10.64%,研究组低于对照组,但差异无统计学意义(χ^(2)=0.137,P>0.05)。结论瑞舒伐他汀钙片联合曲美他嗪治疗冠心病可提高临床疗效,改善患者的心功能,安全性尚可,值得推广与应用。
Objective To analyze the clinical efficacy of rosuvastatin calcium tablets combined with trimetazidine in the treatment of coronary heart disease.Methods The 94 patients with coronary heart disease treated in the hospital from August 2019 to August 2021 were selected for retrospective analysis.According to the random number table method,they were divided into the control group and the study group according to the ratio of 1:1.The control group was treated with trimetazidine,and the study group was treated with rosuvastatin calcium tablets combined with trimetazidine.The therapeutic effects and cardiac function indexes before and after treatment were compared between the two groups,and the adverse reactions of the two groups were observed.Results The effective rates of the study group and control group were 95.74% and 80.85%,respectively,the study group was higher than the control group,and the difference was statistically significant(χ^(2)=5.045,P<0.05).Before treatment,there was no significant difference in the levels of cardiac function indexes between the two groups of patients(P>0.05).After treatment,both groups improved,the LVEF of the study group was higher than that of the control group,and the LVEDD and LVESD were lower than those of the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group and the control group were 6.38% and 10.64%,respectively,and the study group was lower than the control group,but the difference was not statistically significant(χ^(2)=0.137,P>0.05).Conclusion Rosuvastatin calcium tablets combined with trimetazidine in the treatment of coronary heart disease can improve the clinical efficacy and improve the cardiac function of patients.The safety is acceptable,and it is worthy of promotion and application.
作者
韩佳芮
李瑞凤
HAN Jiarui;LI Ruifeng(Department of Cardiology,Rizhao Hospital of Traditional Chinese Medicine,Rizhao,Shandong Province,276800 China)
出处
《世界复合医学》
2022年第2期195-198,共4页
World Journal of Complex Medicine
关键词
冠心病
瑞舒伐他汀钙片
曲美他嗪
效果
不良反应
Coronary heart disease
Rosuvastatin calcium tablet
Trimetazidine
Effect
Adverse reaction
